1 2 3 4 5 6 7 8 9 10 11 12 13 14 Harada R, Okamura N, Furumoto S, et al. 18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57(2):208–214. doi:10.2967/jnumed.115.164848.
Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18FTHK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25. doi:10.1186/s13195-017-0253-y.
Harada R, Ishiki A, Kai H, et al. Correlations of 18F-THK5351 PET with postmortem burden of tau and
astrogliosis in Alzheimer disease. J Nucl Med. 2018;59(4):671–674. doi:10.2967/jnumed.117.197426.
Tago T, Furumoto S, Okamura N, et al. Structure-activity relationship of 2-arylquinolines as PET
imaging tracers for tau pathology in Alzheimer disease. J Nucl Med. 2016;57(4):608–614. doi:10.2967/
jnumed.115.166652.
Ishibashi K, Kameyama M, Miura Y, Toyohara J, Ishii K. Head-to-Head Comparison of the Two MAO-B
Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients with Neurological
Disorders. Clin Nucl Med. 2021;46(1):e31-e33. doi:10.1097/RLU.0000000000003197.
Greicius M. Resting-state functional connectivity in neuropsychiatric disorders. Curr Opin Neurol.
2008;21(4):424–430. doi:10.1097/WCO.0b013e328306f2c5.
Menon V. Large-scale brain networks and psychopathology: A unifying triple network model. Trends Cogn
Sci. 2011;15(10):483–506. doi:10.1016/j.tics.2011.08.003.
Dai Z, Yan C, Li K, et al. Identifying and mapping connectivity patterns of brain network hubs in
Alzheimer’s disease. Cereb Cortex. 2015;25(10):3723–3742. doi:10.1093/cercor/bhu246.
Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer’s
disease from healthy aging: Evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101(13):4637–
4642. doi:10.1073/pnas.0308627101.
Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of
the striatum in Parkinson’s disease. Brain. 2012;135(Pt 12):3699–3711. doi:10.1093/brain/aws281.
Kawabata K, Watanabe H, Hara K, et al. Distinct manifestation of cognitive deficits associate with
different resting-state network disruptions in non-demented patients with Parkinson’s disease. J Neurol.
2018;265(3):688–700. doi:10.1007/s00415-018-8755-5.
Yao N, Shek-Kwan Chang R, Cheung C, et al. The default mode network is disrupted in parkinson’s disease
with visual hallucinations. Hum Brain Mapp. 2014;35(11):5658–5666. doi:10.1002/hbm.22577.
Yokoi T, Watanabe H, Yamaguchi H, et al. Involvement of the precuneus/posterior cingulate cortex is
significant for the development of Alzheimer’s disease: A PET (THK5351, PiB) and resting fMRI study.
Front Aging Neurosci. 2018;10:304. doi:10.3389/fnagi.2018.00304.
Yoneyama N, Watanabe H, Kawabata K, et al. Severe hyposmia and aberrant functional connectivity in
cognitively normal Parkinson’s disease. PLoS One. 2018;13(1):e0190072. doi:10.1371/journal.pone.0190072.
Nagoya J. Med. Sci. 85. 758–771, 2023
769
doi:10.18999/nagjms.85.4.758
Yusuke Yoshida et al
15 Song Z, Insel PS, Buckley S, et al. Brain amyloid-β burden is associated with disruption of intrinsic
functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci.
2015;35(7):3240–3247. doi:10.1523/JNEUROSCI.2092-14.2015.
16 Lim HK, Nebes R, Snitz B, et al. Regional amyloid burden and intrinsic connectivity networks in cognitively
normal elderly subjects. Brain. 2014;137(Pt 12):3327–3338. doi:10.1093/brain/awu271.
17 Moeller JR, Strother SC. A regional covariance approach to the analysis of functional patterns in positron
emission tomographic data. J Cereb Blood Flow Metab. 1991;11(2):A121-A135. doi:10.1038/jcbfm.1991.47.
18 Alexander GE, Moeller JR. Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: A principal component approach to modeling brain function in disease. Hum Brain
Mapp. 1994;2(1–2):79–94. doi:10.1002/hbm.460020108.
19 Spetsieris P, Ma Y, Peng S, et al. Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp. 2013;(76):50319. doi:10.3791/50319.
20 Shigemoto Y, Sone D, Ota M, et al. Voxel-based correlation of 18F-THK5351 accumulation and gray
matter volume in the brain of cognitively normal older adults. EJNMMI Res. 2019;9(1):81. doi:10.1186/
s13550-019-0552-3.
21 Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s Cognitive Examination Revised
(ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21(11):1078–
1085. doi:10.1002/gps.1610.
22 Fazekas F, Kleinert R, Offenbacher H, et al. The morphologic correlate of incidental punctate white matter
hyperintensities on MR images. AJNR Am J Neuroradiol. 1991;12(5):915–921.
23 Verdurand M, Bort G, Tadino V, Bonnefoi F, Le Bars D, Zimmer L. Automated radiosynthesis of the Pittsburg compound-B using a commercial synthesizer. Nucl Med Commun. 2008;29(10):920–926. doi:10.1097/
MNM.0b013e328304e0e1.
24 Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human
brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224–247. doi:10.1002/
hbm.10123.
25 Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment
and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain.
2009;132(Pt 5):1355–1365. doi:10.1093/brain/awp062.
26 Bourgeat P, Chételat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related
to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74(2):121–127. doi:10.1212/
WNL.0b013e3181c918b5.
27 Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and
Alzheimer disease. Ann Neurol. 2011;69(1):181–192. doi:10.1002/ana.22248.
28 Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive
decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–367.
doi:10.1016/S1474-4422(13)70044-9.
29 Niethammer M, Tang CC, Feigin A, et al. A disease-specific metabolic brain network associated with
corticobasal degeneration. Brain. 2014;137(Pt 11):3036–3046. doi:10.1093/brain/awu256.
30 Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states with
whole-brain connectivity patterns. Cereb Cortex. 2012;22(1):158–165. doi:10.1093/cercor/bhr099.
31 Bagarinao E, Watanabe H, Maesawa S, et al. Identifying the brain’s connector hubs at the voxel level using
functional connectivity overlap ratio. Neuroimage. 2020;222:117241. doi:10.1016/j.neuroimage.2020.117241.
32 van den Heuvel MP, Sporns O. Network hubs in the human brain. Trends Cogn Sci. 2013;17(12):683–696.
doi:10.1016/j.tics.2013.09.012.
33 Bertolero MA, Yeo BTT, D’Esposito M. The modular and integrative functional architecture of the human
brain. Proc Natl Acad Sci U S A. 2015;112(49):E6798-E6807. doi:10.1073/pnas.1510619112.
34 Bertolero MA, Yeo BTT, D’Esposito M. The diverse club. Nat Commun. 2017;8(1):1277. doi:10.1038/
s41467-017-01189-w.
35 Bertolero MA, Yeo BTT, Bassett DS, D’Esposito M. A mechanistic model of connector hubs, modularity
and cognition. Nat Hum Behav. 2018;2(10):765–777. doi:10.1038/s41562-018-0420-6.
36 Jeon S, Kang JM, Seo S, et al. Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging,
Tau PET, and Amyloid PET. Front Aging Neurosci. 2019;11:211. doi:10.3389/fnagi.2019.00211.
37 Nam G, Jeong HJ, Kang JM, et al. 18F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal
Dementia. Dement Neurocogn Disord. 2018;17(4):163–173. doi:10.12779/dnd.2018.17.4.163.
38 Son HJ, Oh JS, Roh JH, et al. Differences in gray and white matter 18F-THK5351 uptake between behavioralvariant frontotemporal dementia and other dementias. Eur J Nucl Med Mol Imaging. 2019;46(2):357–366.
Nagoya J. Med. Sci. 85. 758–771, 2023
770
doi:10.18999/nagjms.85.4.758
Aging network changes in mPFC/putamen
doi:10.1007/s00259-018-4125-x.
39 Yoon CW, Jeong HJ, Seo S, et al. 18F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary
Progressive Aphasia. Dement Neurocogn Disord. 2018;17(3):110–119. doi:10.12779/dnd.2018.17.3.110.
40 Kim HJ, Cho H, Park S, et al. THK5351 and flortaucipir PET with pathological correlation in a CreutzfeldtJakob disease patient: a case report. BMC Neurol. 2019;19(1):211. doi:10.1186/s12883-019-1434-z.
41 Ng KP, Therriault J, Kang MS, et al. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]
THK5351 uptake in progressive supranuclear palsy. Neuroimage Clin. 2019;24:102091. doi:10.1016/j.
nicl.2019.102091.
42 Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology
associated with human aging. Acta Neuropathol. 2014;128(6):755–766. doi:10.1007/s00401-014-1349-0.
43 Tong J, Meyer JH, Furukawa Y, et al. Distribution of monoamine oxidase proteins in human brain: Implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33(6):863–871. doi:10.1038/jcbfm.2013.19.
44 Levitt P, Pintart JE, Breakefieldt XO. Immunocytochemical demonstration of monoamine oxidase B in
brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A. 1982;79(20):6385–6389. doi:10.1073/
pnas.79.20.6385.
45 Ekblom J, Jossan SS, Bergström M, Oreland L, Walum E, Aquilonius SM. Monoamine oxidase-B in
astrocytes. Glia. 1993;8(2):122–132. doi:10.1002/glia.440080208.
46 Lemoine L, Gillberg PG, Svedberg M, et al. Comparative binding properties of the tau PET tracers
THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9(1):96.
doi:10.1186/s13195-017-0325-z.
47 Bagarinao E, Watanabe H, Maesawa S, et al. Reorganization of brain networks and its association with
general cognitive performance over the adult lifespan. Sci Rep. 2019;9(1):11352. doi:10.1038/s41598-01947922-x.
48 Uddin LQ, Kelly AM, Biswal BB, Castellanos FX, Milham MP. Functional connectivity of default mode
network components: correlation, anticorrelation, and causality. Hum Brain Mapp. 2009;30(2):625–637.
doi:10.1002/hbm.20531.
49 de Haan W, Mott K, van Straaten EC, Scheltens P, Stam CJ. Activity dependent degeneration explains
hub vulnerability in Alzheimer’s disease. PLoS Comput Biol. 2012;8(8):e1002582. doi:10.1371/journal.
pcbi.1002582.
References End
Nagoya J. Med. Sci. 85. 758–771, 2023
771
doi:10.18999/nagjms.85.4.758
...